StockNoteStockNote
Enlie Pharmaceutical Joint Stock Company (BCP), formerly known as Song Be Pharmaceutical Company, registered its business for the first time on December 29, 2005. The company operates mainly in the field of manufacturing and distributing pharmaceuticals, pharmaceutical materials and medical supplies. The company has a GMP-standard factory and many laboratories, storage systems that meet the standards of drug testing and storage. BCP has built a distribution system and retail pharmacy, concentrated in the southern provinces. On September 14, 2015, the first trading day on the UPCOM market.
BCP currently has a market capitalization of roughly VND 60 billion, placing it in the small-cap group on the Vietnamese stock market. Its current P/E of 23x is 0% above its own 1-year average (23x), suggesting the stock is trading richer than its historical norm. P/B stands at 1,6x, 7% above its multi-year average of 1,5x. Return on equity (ROE) is at 7,2%, up from 1% the year before. Its debt-to-equity ratio of 1,2x is moderate, reflecting a balanced capital structure. In 2025, revenue grew 22% year-on-year while after-tax profit grew 656%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Unit: VND billion. Growth (%) vs. previous period.
Not enough data for this period.
Unit: VND billion. Year-end values; current year uses latest session.
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.